Metsera, Inc. (NASDAQ:MTSR) shows promising Phase 1 results for MET-233i, an amylin analog with significant weight loss effects. The company aims to develop innovative treatments for obesity and metabolic diseases, positioning itself as a high-potential biotech stock.